476617-51-3
中文名称 | 476617-51-3 |
---|---|
中文同义词 | |
英文名称 | Bay 41-4109 (less active enantiomer) |
英文同义词 | Bay 41-4109 (less active enantiomer);BAY41-4109 LESS ACTIVE ENANTIOMER; BAY-41-4109 LESS ACTIVE ENANTIOMER; BAYER 41-4109 LESS ACTIVE ENANTIOMER;Bayer 41-4109 less active enantiomer;methyl (4S)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate;5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4S)-;Bayer 41-4109 S-enantiomer |
CAS号 | 476617-51-3 |
分子式 | C18H13ClF3N3O2 |
分子量 | 395.76 |
EINECS号 | |
相关类别 | |
Mol文件 | 476617-51-3.mol |
结构式 |
476617-51-3 性质
储存条件 | Store at -20°C |
---|---|
溶解度 | 二甲基亚砜:≥ 37 mg/ml(93.49 mM) |
IC50: 53 nM (HBV, Bay 41-4109)
BAY 41-4109 is able to both accelerate and misdirect capsid assembly in vitro . Preformed capsids are stabilized by BAY 41-4109, up to a ratio of one inhibitor molecule per two dimers. BAY 41-4109 is equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with IC 50 s of 32.6 and 132 nM in HepG2.2.15 cells, respectively. HBV DNA and HBcAg are inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition.
BAY 41-4109 reduces viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC. BAY 41 -4109 reduces hepatitis B virus core antigen (HBcAg) in livers of HBV-transgenic mice. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations, about 60% in rats and dogs. BAY41-4109 inhibits virus production in vivo by a mechanism that targets the viral capsid.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2023/03/20 | HY-100029B | 476617-51-3 Bay 41-4109 (less active enantiomer) | 476617-51-3 | 10mM * 1mLin DMSO | 2873元 |
2023/03/20 | HY-100029B | 476617-51-3 Bay 41-4109 (less active enantiomer) | 476617-51-3 | 5mg | 3300元 |